{"filings":[{"id":91273,"accession_number":"0001493152-26-015413","cik":109657,"company_name":"GT Biopharma, Inc.","ticker":"GTBP","form_type":"8-K","filed_at":"2026-04-07T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"GT Biopharma enters agreement with Univ. of Minnesota for Phase 1a/1b trial of GTB-5550","event_type":"other_material","confidence":"high","bullets":["Agreement for IND 169118 GTB-5550 (camB7-H3 TriKE) in advanced solid tumors that failed prior therapy.","University of Minnesota will sponsor as investigator-initiated Phase 1a/1b trial.","Budget of up to $3.8 million over three years, funded by GT Biopharma.","Agreement effective April 3, 2026; 30-day termination clause for either party."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101259,"accession_number":"0001493152-26-008442","cik":109657,"company_name":"GT Biopharma, Inc.","ticker":"GTBP","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["4.02","9.01"],"status":"ready","headline":"GT Biopharma restates Q2/Q3 2025 financials; Greenshoe Rights liability misclassified","event_type":"other_material","confidence":"high","bullets":["Audit committee concluded non-reliance on Q2 and Q3 2025 Form 10-Q after finding Greenshoe Rights should have been liability under ASC 480.","Restatement adds $28.7M liability and loss on initial recognition in Q2; net loss restated to $30.2M from $1.4M.","For Q3, change in fair value of Greenshoe Rights added $11.4M income; net loss restated to $22.6M from $5.3M.","Greenshoe Rights liability extinguished and reclassified to equity in September 2025 after redemption rights waiver.","Company plans to file amended 10-Qs for affected periods and includes restated data in 2025 10-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117614,"accession_number":"0001493152-25-025162","cik":109657,"company_name":"GT Biopharma, Inc.","ticker":"GTBP","form_type":"8-K","filed_at":"2025-11-26T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"GT Biopharma receives Nasdaq delisting notice for low bid price","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified GT Biopharma on Nov 20, 2025 that stock closed below $1 for 30 consecutive days, violating Minimum Bid Price Requirement.","Company has 180 calendar days until May 19, 2026 to regain compliance by closing at $1 for at least 10 consecutive business days.","If not cured, may qualify for additional 180-day period if it meets other listing standards and notifies Nasdaq of intent to reverse split.","Company says it will monitor bid price and assess options; no assurance compliance will be regained."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117613,"accession_number":"0001493152-25-022631","cik":109657,"company_name":"GT Biopharma, Inc.","ticker":"GTBP","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"GT Biopharma reports Q3 2025 net loss of $3.1M; cash $2.6M funds into Q1 2026","event_type":"earnings","confidence":"high","bullets":["Net loss of $3.1M for Q3 2025 improved from $3.4M in Q3 2024.","Cash and equivalents $2.6M expected to fund operations into Q1 2026.","R&D expenses fell to $0.6M from $1.3M due to lower production and material costs.","Phase 1 GTB-3650 trial now in Cohort 4 at 10 µg/kg/day; next update Q1 2026.","GTB-5550 IND submission for B7H3 tumors expected late Dec 2025 or Jan 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.84,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134046,"accession_number":"0001493152-25-015725","cik":109657,"company_name":"GT Biopharma, Inc.","ticker":"GTBP","form_type":"8-K","filed_at":"2025-09-26T23:59:59+00:00","items":["3.03","9.01"],"status":"ready","headline":"GT Biopharma Series L Preferred holders waive redemption rights – all holders now in agreement","event_type":"other_material","confidence":"high","bullets":["All Series L 10% Convertible Preferred Stock holders have waived redemption rights under Section 10 of the Certificate of Designations.","Additional holder provided waiver on September 25, 2025, completing the agreement across all holders.","Waiver eliminates potential redemption trigger that could require cash outlay, improving liquidity.","No financial impact disclosed; modification alters preferred stockholder rights."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134045,"accession_number":"0001493152-25-014684","cik":109657,"company_name":"GT Biopharma, Inc.","ticker":"GTBP","form_type":"8-K","filed_at":"2025-09-23T23:59:59+00:00","items":["3.03","9.01"],"status":"ready","headline":"GT Biopharma series L preferred holders waive redemption rights permanently","event_type":"other","confidence":"high","bullets":["Holders of Series L 10% Convertible Preferred Stock waived redemption rights under Section 10 of the Certificate of Designations.","Waivers were provided on September 17, 18, and 23, 2025, and are permanent.","Waiver does not affect other rights of the preferred stockholders under the Certificate of Designations.","The company requested the waiver; certain holders countersigned the form of waiver."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134044,"accession_number":"0001493152-25-012479","cik":109657,"company_name":"GT Biopharma, Inc.","ticker":"GTBP","form_type":"8-K","filed_at":"2025-08-29T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"GT Biopharma renews CEO Michael Breen for two-year term, effective April 29, 2025","event_type":"leadership","confidence":"high","bullets":["CEO Michael Breen's employment renewed for two years from April 29, 2025, with automatic two-year renewals unless 90-day notice given.","Breen continues as Executive Chairman and CEO; may perform duties from UK or elsewhere outside US.","Amendment No. 3 signed August 26, 2025, retroactively effective April 29, 2025.","No other changes to Breen's compensation or benefits under the existing employment agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134043,"accession_number":"0001641172-25-020847","cik":109657,"company_name":"GT Biopharma, Inc.","ticker":"GTBP","form_type":"8-K","filed_at":"2025-07-24T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"GT Biopharma stockholders approve share issuance for May 2025 financings and omnibus plan amendment","event_type":"other","confidence":"high","bullets":["All four director nominees (Breen, Casamento, Kramer, Mun-Gavin) elected with 1.18M+ votes each, no votes under 14K.","Ratification of Weinberg & Company as FY 2025 auditor passed: 1.79M for, 59K against.","Non-binding advisory vote on executive compensation approved: 1.17M for, 20K against.","Approved issuance of up to 19.99% of outstanding common stock related to May 2025 purchase agreements and convertible preferred.","Amendment No. 1 to 2022 Omnibus Incentive Plan, increasing shares by 583,334, approved: 1.15M for, 35K against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150799,"accession_number":"0001641172-25-014700","cik":109657,"company_name":"GT Biopharma, Inc.","ticker":"GTBP","form_type":"8-K","filed_at":"2025-06-11T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"GT Biopharma appoints new director, amends equity facility to raise up to $20M","event_type":"other_material","confidence":"high","bullets":["Andrew Ritter resigned from board effective June 9, 2025.","David C. Mun-Gavin appointed as director and chair of compensation committee on June 10, 2025.","Amendment to Common Shares Purchase Agreement increases Bristol Capital's beneficial ownership limit to 9.99%.","Equity facility remains at $20M; change gives more flexibility for future stock sales."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150798,"accession_number":"0001641172-25-012481","cik":109657,"company_name":"GT Biopharma, Inc.","ticker":"GTBP","form_type":"8-K","filed_at":"2025-05-27T23:59:59+00:00","items":["1.01","3.02","3.03","5.03","9.01"],"status":"ready","headline":"GT Biopharma expands private placement to $5.95M, adds new investor Marzilli","event_type":"other_material","confidence":"high","bullets":["Increased Series L preferred offering to 6,612 shares ($5.95M) from 6,056 shares ($5.45M) via First Amendment on May 21, 2025.","Added Robert A. Marzilli as new purchaser; Majority Purchasers (Five Narrow Lane, Bristol Capital) consented.","Filed Certificate of Increase raising authorized Series L shares from 28,056 to 30,630.","Greenshoe right: Purchasers may buy up to $24.0M additional preferred stock on same terms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}